VP Medicine Development Leader- Oncology

NOTE:

Posting end date:
Friday, January 23, 2026.

At GSK, we have bold ambitions for patients, aiming to positively impact the health of 2.5 billion people by the end of the decade. Our R&D focuses on discovering and delivering vaccines and medicines, combining our understanding of the immune system with cutting‑edge technology to transform people’s lives. GSK fosters a culture ambitious for patients, accountable for impact, and committed to doing the right thing, making sure that we focus our efforts on accelerating significant assets that meet patients’ needs and have the highest probability of success.

We’re uniting science, technology, and talent to get ahead of disease together.
Find out more:

The VP Medicine Development Leader (MDL) is to strategically lead the optimal global development of a medicine, acting as the single point of accountability for the medicine from C2P2 to approval in first major market, but substantially contributing and influencing from pre‑C2P2 to post‑launch life‑cycle management, to ultimately deliver differentiated medicines of value.

By working with the various stakeholders across R&D and Pharma, the MDL defines the strategic vision and operational plan for the medicine, aligning it with the overall organizational strategy. The VP MDL creates and leads the matrix Medicine Development Team (MDT), which has responsibility for representing all the various R&D and commercial disciplines required to optimally deliver the development of the medicine (including clinical development, medical affairs, safety, regulatory, commercial and product development and manufacturing, amongst others).

Please note:

This position requires an on‑site office‑based presence 2 to 3 days a week in the UK (London or Stevenage) or US (Collegeville/Upper Providence, PA or Waltham. MA).

• Act as a single point of accountability in GSK for all aspects of a medicine in development globally from C2P2 to approval in first major markets.
• In addition to the overall leadership role, the MDL should provide key support to the Early Development Team (EDT) leading up to C2P2 to ensure smooth transfer of accountability and a successful C2P2 and transition from phase 1 to phase 2.
• In addition to the overall leadership role, the MDL should provide key support to the Medicines Commercialisation Team post-approval in first major markets ensuring that the MDT provide optimal support to both registration and lifecycle management.
• Selects members of the MDT, in consultation with the line leaders, and leads this multi-disciplinary matrix team; supports differentiated development for team members; owns the performance of MDT and partners with line managers to drive performance
• Establishes a compelling vision for the medicine; positions the medicine within the R&D strategy taking the competitive landscape into account;
  Translate GSK’s strategy into asset strategy and actionable plans for multiple areas or functions.
• Delivers differentiated medicines of value for patients, stakeholders and markets, through an evidence package that supports regulatory approval, market access, and product life cycle.
• Delivers the Medicine Development Strategy that is aligned with the R&D disease strategy, as well as the asset Medicine Vision and Medicine Profile.
• Prioritizes and maximizes the asset’s portfolio options including developing multiple indications. Makes clear evidence‑based go / no go / accelerate decisions, based on whether the results fulfil the strategy set out for the medicine, and identify clear inflection points
• Embeds core processes including cost efficiency, adoption of new technology, risk identification & management, compliance with policy
• Identifies and aligns resources (people and financial), team objectives and strategies behind the vision to ensure successful project completion
• Proactively identifies unmet medical needs that could be addressed through line extensions
• Enhances patient focus by incorporating the voice of the patient into development plans.
• Promotes organizational reputation and drives asset value by engaging and negotiating with internal and external…